^
    Back
    Association details:
    Biomarker:EGFR expression + ALK positive
    Cancer:Non Small Cell Lung Cancer
    Drug Class:PD-L1 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The data in the second-line setting suggest that PD-1/PD-L1 monotherapy is less effective irrespective of PD-L1 expression in EGFR+/ALK+ NSCLC.